Janssen Pharmaceutica N.V.
Clinical trials sponsored by Janssen Pharmaceutica N.V., explained in plain language.
A pharmaceutical company and subsidiary of Johnson & Johnson, developing and marketing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Alzheimer's vaccine trial aims to stop brain protein buildup Results expected Dec 2026 (estimated)
- Psoriatic arthritis drug showdown: which treatment do patients stick with? Results expected Aug 2027 (estimated)
-
New drug combo aims to stall prostate cancer spread
Disease control OngoingThis phase 3 study tests whether adding the drug apalutamide to standard radiotherapy and hormone therapy can delay cancer spread or death in 692 men with high-risk prostate cancer. Participants are randomly assigned to receive either the standard treatment alone or with apalutam…
Phase 3 • Sponsor: Janssen Pharmaceutica N.V., Belgium • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Alzheimer's vaccine trial aims to stop brain protein buildup
Disease control OngoingThis phase 2 study tests a vaccine called JNJ-64042056 in 55 people with very early signs of Alzheimer's (no symptoms yet but tau buildup in the brain). The vaccine is designed to train the immune system to attack tau protein, which forms tangles in Alzheimer's. Participants rece…
Phase 2 • Sponsor: Janssen Pharmaceutica N.V., Belgium • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Psoriatic arthritis drug showdown: which treatment do patients stick with?
Knowledge-focused OngoingThis study follows over 1,300 people with psoriatic arthritis who are starting either guselkumab (Tremfya) or an IL-17 inhibitor as part of their routine care. Researchers will track how long patients continue each treatment and monitor joint swelling and tenderness. The goal is …
Sponsor: Janssen Pharmaceutica N.V., Belgium • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC